NRX Pharmaceuticals (DE:B1Q)
FRANKFURT:B1Q
B1Q Stock Chart & Stats
€2.09
€0.00(0.00%)
At close: 4:00 PM EST
€2.09
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.37 - €4.13
Previous CloseN/A
Volume0.00
Average Volume (3M)203.00
Market Cap
€144.18M
Enterprise Value€70.62M
Total Cash (Recent Filing)€6.71M
Total Debt (Recent Filing)€934.00K
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 17, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding36,228,992
10 Day Avg. Volume609
30 Day Avg. Volume203
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.95Price Target Upside1476.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.07
Revenue Forecast (FY)€40.40M
Bulls Say, Bears Say
Bulls Say
KETAFREE Regulatory & Manufacturing ProgressPreliminary FDA bioequivalence with only minor items, VAI reclassification, and a 1M‑unit commercial batch plus blow‑fill‑seal (>10x throughput) create a durable path to U.S. launch. Scalable domestic manufacturing reduces supply risk, supports margin improvement and sustainable commercial supply for clinics and hospitals.
NRX‑100 NDA Backed By Extensive RWESubmitting an NDA supported by large real‑world evidence and patient data provides regulatory leverage and a competitive advantage versus peers reliant on limited trials. Strong RWE can shorten development risk, broaden label potential, and help payer discussions — durable benefits for approval and commercialization.
HOPE Clinic Network & Integrated CommercializationExpanding HOPE clinics and integrating TMS capacity plus AI monitoring creates a proprietary commercialization channel and real‑world data pipeline. Owning distribution endpoints helps product adoption, shortens feedback loops, and reduces reliance on third‑party wholesalers over the medium term.
Bears Say
Heavy Cash Burn And Negative EquitySustained negative cash flow and an accumulated deficit limit financial flexibility and increase funding dependence. Persistent TTM burn near $15M and negative shareholders' equity constrain investment capacity, raise refinancing risk, and make multi‑program execution vulnerable if expected milestones or financing do not materialize.
Reliance On External Financing And Dilution RiskThe company repeatedly relies on equity issuances and ATM facilities to fund operations. Planned underwritten offerings and an expanded incentive share pool materially increase dilution risk. Ongoing capital raises can alter capital structure and shareholder economics and are likely required until sustained product revenues arrive.
Regulatory Timing & Funding Execution RiskCritical milestones hinge on FDA timing, statistical‑plan agreement, and anticipated nondilutive grants. Delays or unfavorable regulatory determinations or slower grant awards would push milestones, raise incremental financing needs, and complicate commercialization timing, stressing execution across multiple late‑stage programs.
NRX Pharmaceuticals News
B1Q FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was €1.37 and its highest was €4.13 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is €144.18M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Aug 17, 2026 which is in 74 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on May 18, 2026. The company reported -€0.034 earnings per share for the quarter, missing the consensus estimate of €0.18 by -€0.214.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.06.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 36,228,992 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -€0.034 in its last earnings report, missing expectations of €0.18. Following the earnings report the stock price went up 7.895%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:B1Q
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.95 (1476.49% Upside)
€32.95 (1476.49% Upside)
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.87%
12-Months-Change
Fundamentals
Return on Equity
107.73%
Trailing 12-Months
Asset Growth
56.82%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
B1Q Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial forward progress across multiple fronts: near-term regulatory and manufacturing milestones for KETAFREE, an NRX-100 NDA supported by >65,000-patient RWE, FDA clearance to proceed with a sizable NRX-101 TMS augmentation trial (MIND1), expansion of HOPE clinics, and acquisition of Geneuro assets to broaden the pipeline. Financially, reported net loss improved materially (a 74% reduction year-over-year) and the company raised ~$7.0M post-quarter, while becoming debt-free. Counterbalancing these positives are near-term operational cash sensitivity, increased operating losses driven by higher R&D and G&A spend, ongoing regulatory timing risk, the need to build commercial channels (particularly to displace compounding pharmacy supply to clinics), and dependence on anticipated nondilutive funding for certain programs. Overall, the balance of concrete regulatory/operational advances and capital actions alongside manageable but material execution and timing risks supports a constructive outlook.View all DE:B1Q earnings summariesB1Q Stock 12 Month Forecast
Average Price Target
€32.95
▲(1476.49% Upside)
Technical Analysis
CervoMed
―
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Options Prices
Currently, No data available
---